HBsAg screening is an important part of antenatal care because hepatitis B virus (HBV) can be transmitted from a mother living with hepatitis B to her baby around the time of birth.

Identifying hepatitis B during pregnancy gives the healthcare team time to assess the mother's infection, determine whether additional treatment or prophylaxis is appropriate, and plan important preventive measures for the newborn.

The initial screening test commonly looks for hepatitis B surface antigen (HBsAg).

A Reactive HBsAg result during pregnancy does not mean that the baby will definitely acquire hepatitis B. Effective maternal assessment and timely newborn preventive care can greatly reduce the risk of mother-to-child transmission.

What Is HBsAg?

HBsAg stands for hepatitis B surface antigen.

It is a viral antigen associated with hepatitis B virus.

Detection of HBsAg generally indicates current HBV infection.

Importantly:

• HBsAg is an antigen, not an antibody.
• A Reactive HBsAg result does not by itself tell whether infection is acute or chronic.
• HBsAg does not measure HBV viral load.
• HBsAg does not show how much liver damage is present.

For the complete explanation, read:

HBsAg Rapid Test Kit Complete Guide

Why Is Hepatitis B Screening Important During Pregnancy?

Mother-to-child transmission is an important route by which hepatitis B can be acquired.

Infection acquired around birth or during early childhood carries a much greater risk of becoming chronic than infection acquired later in life.

Antenatal screening provides an opportunity to identify maternal HBV infection before delivery so that appropriate preventive measures can be organised.

The purpose is therefore not simply to obtain an HBsAg result. The real goal is:

Screen → Identify → Assess → Prevent transmission → Link mother and baby to appropriate care.

When Should HBsAg Testing Be Done During Pregnancy?

HBsAg screening should be performed early during antenatal care according to applicable national and clinical guidance.

In India, National Viral Hepatitis Control Programme material recommends screening pregnant women for HBsAg at the first antenatal visit.

Early screening is useful because a Reactive result leaves sufficient time to:

• Arrange appropriate medical evaluation
• Confirm and characterise maternal HBV infection
• Assess HBV DNA where appropriate
• Determine whether maternal antiviral prophylaxis is indicated
• Plan newborn hepatitis B prevention
• Coordinate delivery and postnatal follow-up

Is HBsAg Screening Part of Routine Antenatal Infection Screening?

Yes.

HBsAg screening is closely connected with antenatal testing for HIV and syphilis.

WHO's Triple Elimination framework focuses on preventing mother-to-child transmission of:

• HIV
• Syphilis
• Hepatitis B

These infections require different tests and different treatment pathways, but pregnancy provides an important opportunity to screen for them early.

Read:

Antenatal Infection Screening: HIV, Syphilis, Hepatitis B & HCV

What Test Is Used to Screen for Hepatitis B During Pregnancy?

The key screening marker is HBsAg — hepatitis B surface antigen.

HBsAg may be detected using:

• Laboratory immunoassays
• Quality-assured rapid diagnostic tests in appropriate settings

The exact test and specimen type depend on the product and healthcare setting.

Can an HBsAg Rapid Test Be Used During Pregnancy?

An HBsAg rapid test can be used as an initial screening tool where appropriate and according to its intended use.

However:

A rapid screening test is only the first step in the pathway when HBsAg is detected.

A Reactive result should lead to appropriate laboratory and medical evaluation rather than being used alone to make decisions about maternal treatment or newborn management.

What Does a Non-Reactive HBsAg Result Mean During Pregnancy?

A Non-Reactive result means hepatitis B surface antigen was not detected by the assay.

This is generally reassuring regarding current HBsAg detection.

However:

HBsAg Non-Reactive does not automatically mean that the pregnant woman is immune to hepatitis B.

Immunity is assessed using another marker called anti-HBs.

HBsAg, anti-HBs and anti-HBc answer different questions.

Does HBsAg Non-Reactive Mean Hepatitis B Vaccination Is Not Needed?

Not necessarily.

An HBsAg test does not determine whether adequate anti-HBs immunity is present.

Vaccination requirements should be assessed according to vaccination history, clinical circumstances and applicable healthcare guidance.

Pregnant women should discuss vaccination questions with their antenatal healthcare professional rather than interpreting HBsAg alone as proof of immunity.

What Does a Reactive HBsAg Result Mean During Pregnancy?

A Reactive HBsAg result means hepatitis B surface antigen has been detected by the screening test.

This indicates a need for further hepatitis B evaluation.

It does not by itself answer:

• Whether infection is acute or chronic
• When infection occurred
• What the HBV DNA level is
• How much liver damage exists
• Whether maternal antiviral prophylaxis is required
• Whether the baby has hepatitis B

For the detailed follow-up pathway, read:

HBsAg Reactive Result: What It Means & What Happens Next

Does Reactive HBsAg Mean the Baby Has Hepatitis B?

No.

A maternal Reactive HBsAg test identifies HBV infection in the mother.

It does not diagnose hepatitis B in the baby.

Instead, it identifies a pregnancy where preventive measures for mother-to-child transmission become particularly important.

What Happens After HBsAg Is Reactive During Pregnancy?

The general pathway is:

HBsAg Reactive
↓
Professional HBV evaluation
↓
Additional maternal assessment
↓
HBV DNA and/or other markers where appropriate
↓
Assess need for maternal treatment or prophylaxis
↓
Plan newborn hepatitis B prevention
↓
Maternal and infant follow-up

Why Is HBV DNA Important During Pregnancy?

HBV DNA measures hepatitis B viral genetic material in the blood.

It provides information about viral replication and is different from an HBsAg test.

HBsAg	HBV DNA
Detects hepatitis B surface antigen	Detects hepatitis B viral DNA
Important screening/detection marker	Assesses viral replication
Does not provide viral load	Can provide an HBV viral-load measurement
Helps identify maternal HBV infection	Can help determine need for maternal antiviral prophylaxis

What HBV DNA Level Is Important for Preventing Mother-to-Child Transmission?

Current WHO guidance identifies pregnant women who are HBsAg-positive and have an HBV DNA level of 200,000 IU/mL or higher as an important group for whom maternal antiviral prophylaxis is recommended to reduce mother-to-child transmission.

This laboratory result should be interpreted and managed by the treating healthcare team.

A home HBsAg test cannot estimate whether HBV DNA is above or below this threshold.

What If HBV DNA Testing Is Not Available?

Where HBV DNA testing is unavailable, WHO guidance allows HBeAg to be used as an alternative marker for identifying women at higher risk of transmitting HBV to their infant.

WHO's updated hepatitis B guidance also provides options for broader maternal antiviral prophylaxis in settings where access to HBV DNA and HBeAg testing remains limited.

The exact approach should follow current national or institutional protocol.

What Is HBeAg?

HBeAg means hepatitis B e antigen.

It is different from HBsAg.

HBeAg can provide information related to active viral replication and can be useful when assessing transmission risk in pregnancy where HBV DNA testing is not readily available.

However:

HBsAg Reactive ≠ HBeAg Reactive.

They are separate hepatitis B markers.

Can Antiviral Medicine Be Used During Pregnancy to Reduce HBV Transmission?

Yes, when clinically indicated.

Current WHO guidance supports maternal antiviral prophylaxis using tenofovir disoproxil fumarate (TDF) for appropriately selected HBsAg-positive pregnant women to reduce the risk of mother-to-child transmission.

Eligibility and timing should be determined by qualified healthcare professionals according to current guidelines.

Pregnant women should not start, stop or change antiviral treatment based on an online article or home-test result.

When Is Maternal Tenofovir Prophylaxis Started?

WHO's established approach for women with high maternal HBV DNA has used prophylaxis beginning around the 28th week of pregnancy and continuing through at least delivery.

The 2024 WHO hepatitis B guideline also introduced broader options for prophylaxis, including starting from the second trimester in certain programme settings.

The exact timing and duration should be determined by the healthcare team according to:

• HBV DNA or HBeAg result
• Maternal hepatitis B status
• Whether treatment is required for the mother's own health
• Gestational age
• National or institutional guidelines

Is Maternal Antiviral Prophylaxis the Same as Long-Term Hepatitis B Treatment?

Not necessarily.

There are two related but distinct questions:

1. Does the mother need antiviral treatment for her own hepatitis B?

and:

2. Is antiviral prophylaxis needed primarily to reduce mother-to-child transmission?

Some women may meet long-term treatment criteria independent of pregnancy.

Others may receive treatment or prophylaxis specifically because of a high risk of HBV transmission to the baby.

The healthcare professional should distinguish these situations.

What Happens to the Baby After Birth?

Newborn hepatitis B prevention is one of the most important components of the maternal HBV pathway.

WHO recommends that all newborns receive the first dose of hepatitis B vaccine as soon as possible after birth, ideally within 24 hours.

This recommendation applies regardless of whether the mother is known to have hepatitis B.

Why Is the Hepatitis B Birth Dose So Important?

The vaccine given shortly after birth can prevent infection occurring during delivery and early infancy.

The timely birth dose is followed by additional hepatitis B vaccine doses according to the routine infant immunisation schedule.

Completing the vaccine series is essential for long-term protection.

What Happens If the Mother Is HBsAg Reactive?

Newborns of mothers with hepatitis B may require additional measures beyond routine vaccination.

India's National Viral Hepatitis Control Programme material includes:

• Timely hepatitis B birth-dose vaccination
• Hepatitis B immunoglobulin (HBIG) for infants born to HBsAg-positive mothers at designated facilities
• Appropriate maternal referral and follow-up

The exact newborn regimen should be organised by the maternity and neonatal healthcare team.

What Is HBIG?

HBIG stands for hepatitis B immunoglobulin.

It provides passive antibodies against hepatitis B and can provide additional protection for newborns at increased risk of exposure.

HBIG and hepatitis B vaccine are different products:

Hepatitis B Vaccine	HBIG
Stimulates active immune protection	Provides passive antibodies
Part of routine infant immunisation	Used in selected exposure situations
Requires completion of vaccine schedule	Provides immediate additional protection

Does Every Baby Need HBIG?

HBIG use depends on maternal HBsAg status, applicable national policy, availability and clinical guidance.

It should not be confused with the universal hepatitis B birth-dose vaccine.

The hepatitis B birth dose is recommended for all newborns.

HBIG is an additional intervention used for selected high-risk newborns, including infants born to HBsAg-positive mothers under applicable programmes.

Should Delivery Be Planned in a Hospital if HBsAg Is Reactive?

When maternal HBsAg is Reactive, delivery planning should ensure that appropriate newborn hepatitis B prevention can be provided promptly.

Indian NVHCP material recommends institutional delivery pathways for HBsAg-positive pregnant women where hepatitis B birth-dose vaccine and HBIG can be made available.

This makes antenatal identification valuable: the delivery team can prepare in advance rather than discovering maternal HBV status after birth.

Does HBsAg Reactivity Automatically Mean Caesarean Delivery?

No.

HBsAg reactivity by itself should not be treated as an automatic indication for caesarean delivery.

The mode of delivery should be determined by the obstetric team according to maternal and fetal clinical indications.

Can a Mother with Hepatitis B Breastfeed?

Maternal hepatitis B status should be discussed with the obstetric and paediatric healthcare team, particularly so that newborn vaccination and other preventive measures are completed correctly.

Infant-feeding decisions should follow current clinical recommendations rather than being made from the HBsAg result alone.

Does HBsAg Reactivity Mean the Pregnancy Is High Risk?

A Reactive HBsAg result identifies a maternal infection that requires coordinated antenatal care and prevention planning.

Indian NVHCP programme material places HBsAg-positive pregnant women into a specific referral pathway so maternal evaluation and newborn prevention are not missed.

This does not mean that a serious pregnancy complication is inevitable.

Can Hepatitis B Harm the Mother?

HBV primarily affects the liver.

A pregnant woman with hepatitis B may therefore require assessment of:

• ALT
• AST
• Other liver tests
• HBV DNA
• Clinical signs of liver disease
• Whether treatment is required for her own health

The pregnancy visit should therefore link the woman not only to prevention of infant transmission but also to appropriate long-term hepatitis B care.

Does Every HBsAg-Reactive Pregnant Woman Need Long-Term Treatment?

No.

HBsAg detection alone does not establish long-term treatment eligibility.

WHO's hepatitis B treatment recommendations consider factors such as:

• Cirrhosis or significant fibrosis
• HBV DNA
• ALT
• Coinfections
• Other clinical risk factors

A pregnant woman may therefore require:

• Long-term HBV treatment
• Pregnancy-specific prophylaxis
• Monitoring without immediate treatment

depending on her complete assessment.

Should a Pregnant Woman with HBsAg Reactive Be Tested for Hepatitis D?

Hepatitis D virus (HDV) can infect people who have hepatitis B infection.

Current WHO guidance supports anti-HDV testing among HBsAg-positive individuals as a broad preferred approach where feasible.

The treating healthcare team can determine whether HDV testing is indicated and available.

Should HIV and Syphilis Screening Still Be Done?

Yes.

A Reactive HBsAg result tells you nothing about HIV or syphilis status.

These infections require their own tests.

During antenatal care:

Screening Area	Typical Marker
HIV	HIV antibodies and/or antigen depending on assay
Syphilis	Usually treponemal antibodies in a rapid test
Hepatitis B	HBsAg

Reactive HBsAg does not predict the result of HIV or syphilis testing.

What About HCV Testing During Pregnancy?

HCV is another blood-borne viral infection, but it is not simply the fourth component of WHO's HIV-syphilis-HBV Triple Elimination framework.

HCV testing during pregnancy should follow applicable national or institutional protocols and the individual's clinical circumstances.

Does HBsAg Reactive Mean the Partner Has Hepatitis B?

No.

A person's HBsAg result cannot determine another person's HBV status.

However, sexual partners and household members of someone with hepatitis B may be advised to undergo appropriate HBV testing and vaccination assessment.

Can the Partner Be Vaccinated?

Hepatitis B is vaccine-preventable.

If a partner or household contact is susceptible, hepatitis B vaccination can provide protection.

Appropriate testing and vaccination advice should be obtained from a healthcare professional.

Does Pregnancy Change the Meaning of HBsAg?

No.

HBsAg remains hepatitis B surface antigen whether the person is pregnant or not.

Pregnancy changes the clinical importance of the result because maternal HBV infection creates a potential risk of transmission to the baby and therefore triggers additional prevention planning.

Microsidd HBsAg Fast Test Kit Mono Pack

The Microsidd HBsAg Fast Test Kit Mono Pack is designed for initial screening for hepatitis B surface antigen using fingerstick whole blood.

A home rapid test can help identify a person who needs further evaluation, but it should not be used by itself to:

• Measure HBV DNA
• Determine treatment eligibility
• Assess fetal health
• Determine neonatal prophylaxis
• Replace antenatal clinical care

Pregnancy + HBsAg: Complete Pathway at a Glance

First antenatal visit
↓
HBsAg screening
↓

If Non-Reactive:
Continue routine antenatal care and assess hepatitis B vaccination/immunity where clinically appropriate.

If Reactive:
↓
Professional HBV evaluation
↓
Assess HBV DNA / other markers where appropriate
↓
Assess maternal liver health
↓
Determine treatment or prophylaxis needs
↓
Plan institutional delivery and newborn HBV prevention
↓
Timely hepatitis B birth-dose vaccination
↓
HBIG where indicated under applicable protocol
↓
Complete infant vaccination schedule
↓
Maternal + infant follow-up

Frequently Asked Questions

Is HBsAg testing recommended during pregnancy?

Yes. HBsAg screening is an important component of antenatal infection screening and helps identify maternal hepatitis B infection early enough to plan maternal evaluation and newborn preventive care.

When should HBsAg be tested during pregnancy?

Screening should be performed early in antenatal care. Indian NVHCP material recommends HBsAg screening at the first antenatal visit.

What does Reactive HBsAg mean during pregnancy?

It means hepatitis B surface antigen has been detected and further medical and laboratory evaluation is needed.

Does Reactive HBsAg mean the baby has hepatitis B?

No. Maternal HBsAg reactivity does not diagnose infection in the baby.

Does Reactive HBsAg mean the baby will definitely get hepatitis B?

No. Appropriate maternal assessment and timely newborn preventive measures can substantially reduce mother-to-child transmission risk.

What is HBV DNA and why is it tested during pregnancy?

HBV DNA measures viral genetic material. Maternal viral load helps identify women with a higher risk of transmitting HBV to their baby and can guide antiviral prophylaxis decisions.

What HBV DNA level is important during pregnancy?

Current WHO guidance uses an HBV DNA threshold of 200,000 IU/mL or higher as an important criterion for maternal tenofovir prophylaxis to prevent mother-to-child transmission.

What if HBV DNA testing is not available?

WHO allows HBeAg to